{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-007057","form_type":"8-K/A","ticker":"SNOA","cik":"0001367083","company_name":"Sonoma Pharmaceuticals, Inc.","filed_at":"2023-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.764590+00:00","generated_at":"2026-06-10T01:33:43.160231+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Sonoma Pharmaceuticals files amended 8-K with updated investor presentation; no material new information","bullets":["Amended filing corrects item number from original 8-K dated October 11, 2023.","Investor presentation (October 2023) describes stabilized hypochlorous acid products for dermatology, wound care, etc.","Products are sold directly or via partners in 55 countries; company actively seeks distribution partners.","Presentation contains no financial results, guidance, or material operational updates."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-007057","json":"https://secwatch.observer/filing/0001683168-23-007057.json","markdown":"https://secwatch.observer/filing/0001683168-23-007057.md","text":"https://secwatch.observer/filing/0001683168-23-007057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367083/000168316823007057/0001683168-23-007057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367083/000168316823007057/sonoma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T01:33:43.160231+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}